Ovaj gen kodira jedan tip N-acetiltransferaza. NAT2 izozim funkcioniše tako što aktivira i deaktivira arilaminske i hidrazinske lekove i karcinogene. Polimorfizam ovog gena je odgovoran za N-acetilacioni polimorfizam kojim se ljudska populacija segregira u brze, srednje i spore acetilatornefenotipe. Polimorfizmi NAT2 su takođe povezani za povećanom učestalošću kancera i toksičnošću lekova. Drugi arilaminski N-acetiltransferazni gen (NAT1) je lociran blizo NAT2.[2]
↑Vatsis KP, Weber WW, Bell DA, Dupret JM, Evans DA, Grant DM, Hein DW, Lin HJ, Meyer UA, Relling MV (February 1995). „Nomenclature for N-acetyltransferases”. Pharmacogenetics5 (1): 1–17. DOI:10.1097/00008571-199502000-00001. PMID7773298.
Windmill KF, McKinnon RA, Zhu X, et al. (1997). „The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: functional and localization studies.”. Mutat. Res.376 (1-2): 153–60. DOI:10.1016/S0027-5107(97)00038-9. PMID9202751.
Lan Q, Rothman N, Chow WH, et al. (2003). „No apparent association between NAT1 and NAT2 genotypes and risk of stomach cancer.”. Cancer Epidemiol. Biomarkers Prev.12 (4): 384–6. PMID12692115.
Ochs-Balcom HM, Wiesner G, Elston RC (2007). „A meta-analysis of the association of N-acetyltransferase 2 gene (NAT2) variants with breast cancer.”. Am. J. Epidemiol.166 (3): 246–54. DOI:10.1093/aje/kwm066. PMID17535831.
Sanderson S, Salanti G, Higgins J (2007). „Joint effects of the N-acetyltransferase 1 and 2 (NAT1 and NAT2) genes and smoking on bladder carcinogenesis: a literature-based systematic HuGE review and evidence synthesis.”. Am. J. Epidemiol.166 (7): 741–51. DOI:10.1093/aje/kwm167. PMID17675654.